{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:00:04Z","timestamp":1791907204412,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Key Technologies Research and Development Program","award":["2021YFA1201100"],"award-info":[{"award-number":["2021YFA1201100"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072716"],"award-info":[{"award-number":["82072716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81802433"],"award-info":[{"award-number":["81802433"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82030092"],"award-info":[{"award-number":["82030092"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81720108028"],"award-info":[{"award-number":["81720108028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072659"],"award-info":[{"award-number":["82072659"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871968"],"award-info":[{"award-number":["81871968"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871978"],"award-info":[{"award-number":["81871978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82103006"],"award-info":[{"award-number":["82103006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82072657"],"award-info":[{"award-number":["82072657"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173295"],"award-info":[{"award-number":["82173295"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006606","name":"Tianjin Natural Science Foundation","doi-asserted-by":"crossref","award":["20JCQNJC01330"],"award-info":[{"award-number":["20JCQNJC01330"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019062","name":"Tianjin Research Innovation Project for Postgraduate Students","doi-asserted-by":"publisher","award":["2021YJSB262"],"award-info":[{"award-number":["2021YJSB262"]}],"id":[{"id":"10.13039\/501100019062","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaboration Program of Beijing Tianjin and Hebei","award":["22JCZXJC00120"],"award-info":[{"award-number":["22JCZXJC00120"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemoresistance\u00a0is the\u00a0main\u00a0reason\u00a0for the poor prognosis of\u00a0pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We established a bio-bank of human PDAC organoid models, covering a representative range of PDAC tumor subtypes. We screened a library of 1304 FDA-approved compounds to identify candidates efficiently overcoming chemotherapy resistance. The effects of the compounds were evaluated with a CellTiter-Glo-3D assay, organoid apoptosis assay and in vivo patient-derived xenograft (PDX), patient-derived organoid (PDO) and LSL-Kras\n                      <jats:sup>G12D\/+<\/jats:sup>\n                      ; LSL-Trp53\n                      <jats:sup>R172H\/+<\/jats:sup>\n                      ; Pdx1-Cre (KPC) genetically engineered mouse models. RNA-sequencing, genome editing, sphere formation assays, iron assays and luciferase assays were conducted to elucidate the mechanism.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High-throughput drug screening of chemotherapy-resistant PDOs identified irbesartan, an angiotensin \u2016 type 1 (AT1) receptor antagonist, which could synergistically enhance the ability of chemotherapy to kill PDAC cells. In vitro and in vivo validation using PDO, PDX and KPC mouse models showed that irbesartan efficiently sensitized PDAC tumors to chemotherapy. Mechanistically, we found that irbesartan decreased c-Jun expression by inhibiting the Hippo\/YAP1 pathway and further overcame chemotherapy resistance in PDAC. We also explored c-Jun, a potential target of irbesartan, which can transcriptionally upregulate the expression of key genes involved in stemness maintenance (SOX9\/SOX2\/OCT4) and iron metabolism (FTH1\/FTL\/TFRC). More importantly, we observed that PDAC patients with high levels of c-Jun expression demonstrated poor responses to the current standard chemotherapy regimen (gemcitabine plus nab-paclitaxel). Moreover, patients with PDAC had significant survival benefits from treatment with irbesartan plus a standard chemotherapy regimen in two-center retrospective clinical cohorts and patients with high c-Jun expression exhibited a better response to combination chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Irbesartan could be used in combination with chemotherapy to improve the therapeutic efficacy in PDAC patients with high levels of c-Jun expression. Irbesartan effectively inhibited chemotherapy resistance by suppressing the Hippo\/YAP1\/c-Jun\/stemness\/iron metabolism axis. Based on our findings, we are designing an investigator-initiated phase II clinical trial on the efficacy and safety of irbesartan plus a standard gemcitabine\/nab-paclitaxel regimen in the treatment of patients with advanced III\/IV staged PDAC and are hopeful that we will observe patient benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-023-02671-8","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:01:59Z","timestamp":1683158519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-Jun axis"],"prefix":"10.1186","volume":"42","author":[{"given":"Tianxing","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xupeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenna","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiansuo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"27","key":"2671_CR1","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"JX Hu","year":"2021","unstructured":"Hu JX, Zhao CF, Chen WB, Liu QC, Li QW, Lin YY, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298\u2013321.","journal-title":"World J Gastroenterol"},{"issue":"39","key":"2671_CR2","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.3748\/wjg.v27.i39.6527","volume":"27","author":"A Jain","year":"2021","unstructured":"Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol. 2021;27(39):6527\u201350.","journal-title":"World J Gastroenterol"},{"key":"2671_CR3","doi-asserted-by":"publisher","first-page":"682872","DOI":"10.3389\/fonc.2021.682872","volume":"11","author":"K Miyabayashi","year":"2021","unstructured":"Miyabayashi K, Nakagawa H, Koike K. Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. Front Oncol. 2021;11:682872.","journal-title":"Front Oncol"},{"key":"2671_CR4","doi-asserted-by":"publisher","first-page":"741162","DOI":"10.3389\/fcell.2021.741162","volume":"9","author":"B Gundel","year":"2021","unstructured":"Gundel B, Liu X, Lohr M, Heuchel R. Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models. Front Cell Dev Biol. 2021;9:741162.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"2671_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrc2820","volume":"10","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10(4):241\u201353.","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"2671_CR6","doi-asserted-by":"publisher","first-page":"e101654","DOI":"10.15252\/embj.2019101654","volume":"38","author":"M Bleijs","year":"2019","unstructured":"Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in cancer research. EMBO J. 2019;38(15):e101654.","journal-title":"EMBO J"},{"key":"2671_CR7","doi-asserted-by":"crossref","unstructured":"D'Agosto S, Andreani S, Scarpa A, and Corbo V. Preclinical Modelling of PDA: Is Organoid the New Black? Int J Mol Sci. 2019;20(11):2766.","DOI":"10.3390\/ijms20112766"},{"issue":"1\u20132","key":"2671_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1\u20132):324\u201338.","journal-title":"Cell"},{"issue":"9","key":"2671_CR9","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8(9):1112\u201329.","journal-title":"Cancer Discov"},{"issue":"1\u20132","key":"2671_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1\u20132):324\u201338.","journal-title":"Cell"},{"issue":"11","key":"2671_CR11","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/nm.3973","volume":"21","author":"L Huang","year":"2015","unstructured":"Huang L, Holtzinger A, Jagan I, BeGora M, Lohse I, Ngai N, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med. 2015;21(11):1364\u201371.","journal-title":"Nat Med"},{"issue":"2","key":"2671_CR12","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.xgen.2022.100095","volume":"2","author":"CK Hirt","year":"2022","unstructured":"Hirt CK, Booij TH, Grob L, Simmler P, Toussaint NC, Keller D, et al. Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment. Cell Genom. 2022;2(2):100095.","journal-title":"Cell Genom"},{"issue":"20","key":"2671_CR13","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1038\/emboj.2013.204","volume":"32","author":"M Huch","year":"2013","unstructured":"Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJ, van de Wetering M, et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5\/R-spondin axis. EMBO J. 2013;32(20):2708\u201321.","journal-title":"EMBO J"},{"issue":"15","key":"2671_CR14","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics (Oxford, England). 2017;33(15):2413\u20135.","journal-title":"Bioinformatics (Oxford, England)"},{"issue":"W1","key":"2671_CR15","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488-w93.","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"2671_CR16","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","volume":"184","author":"K Koikawa","year":"2021","unstructured":"Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021;184(18):4753-71 e27.","journal-title":"Cell."},{"key":"2671_CR17","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab TS, Li CP, Okusaka T, O'Neil BH, Reni M, Tabernero J, et al. CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). Journal of Clinical Oncology. 2017;35(15_suppl):TPS4148-TPS.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4148"},{"key":"2671_CR18","doi-asserted-by":"crossref","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6.","DOI":"10.1200\/JCO.2006.07.9525"},{"key":"2671_CR19","unstructured":"Stukov AN, Filatova LV, Gershanovich ML, Semiglazova TI, Zargarova NIJVo. Gemcitabine and lomustine combination in mice with intracranial transplanted lymphosarcoma LIO-1.Vopr Onkol. 2012;58(3):394\u20137."},{"key":"2671_CR20","doi-asserted-by":"crossref","unstructured":"Zhou T, Liu J, Xie Y, Yuan S, Hao JJG. ESE3\/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4. Gut. 2021:gutjnl-2020\u2013321952.","DOI":"10.1136\/gutjnl-2020-321952"},{"issue":"6","key":"2671_CR21","doi-asserted-by":"publisher","first-page":"e1795-e","DOI":"10.1038\/cddis.2015.172","volume":"6","author":"T Namba","year":"2015","unstructured":"Namba T, Kodama R, Moritomo S, Hoshino T, Mizushima T. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3\u03b2-Snail pathway. Cell Death Dis. 2015;6(6):e1795-e.","journal-title":"Cell Death Dis."},{"issue":"3","key":"2671_CR22","first-page":"394","volume":"58","author":"AN Stukov","year":"2012","unstructured":"Stukov AN, Filatova LV, Gershanovich ML, Semiglazova T, Tarasenkova AA, Latinova D, et al. Combined effect of gemcitabine and lomustine in mice with intracranial transplanted lymphosarcoma LIO-1. Vopr Onkol. 2012;58(3):394\u20137.","journal-title":"Vopr Onkol"},{"issue":"4","key":"2671_CR23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12032-015-0578-y","volume":"32","author":"G Holgersson","year":"2015","unstructured":"Holgersson G, Bergstr\u00f6m S, Harmenberg J, Ringbom M, Klockare M, Jerling M, et al. A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. Med Oncol (Northwood, London, England). 2015;32(4):129.","journal-title":"Med Oncol (Northwood, London, England)"},{"issue":"Suppl 12","key":"2671_CR24","first-page":"S278","volume":"10","author":"M Burnier","year":"1999","unstructured":"Burnier M, Brunner HR. Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol. 1999;10(Suppl 12):S278\u201382.","journal-title":"J Am Soc Nephrol"},{"issue":"15","key":"2671_CR25","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1002\/cam4.3229","volume":"9","author":"JE Rogers","year":"2020","unstructured":"Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, et al. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020;9(15):5406\u201315.","journal-title":"Cancer Med"},{"issue":"1","key":"2671_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12885-022-09255-3","volume":"22","author":"AM Delahoussaye","year":"2022","unstructured":"Delahoussaye AM, Abi Jaoude J, Green M, Fujimoto TN, Molkentine J, Garcia Garcia CJ, et al. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. BMC Cancer. 2022;22(1):174.","journal-title":"BMC Cancer"},{"issue":"1","key":"2671_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41421-021-00366-y","volume":"8","author":"X Fan","year":"2022","unstructured":"Fan X, Lu P, Wang H, Bian S, Wu X, Zhang Y, et al. Integrated single-cell multiomics analysis reveals novel candidate markers for prognosis in human pancreatic ductal adenocarcinoma. Cell Discov. 2022;8(1):13.","journal-title":"Cell Discov"},{"issue":"8","key":"2671_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","volume":"6","author":"J Incio","year":"2016","unstructured":"Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, et al. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. Cancer Discov. 2016;6(8):852\u201369.","journal-title":"Cancer Discov"},{"issue":"2","key":"2671_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/1541-7786.MCR-15-0305","volume":"14","author":"U Ehmer","year":"2016","unstructured":"Ehmer U, Sage J. Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res. 2016;14(2):127\u201340.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2671_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1101\/gad.1865810","volume":"24","author":"Z Li","year":"2010","unstructured":"Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. Genes Dev. 2010;24(3):235\u201340.","journal-title":"Genes Dev"},{"key":"2671_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1476-4598-8-37","volume":"8","author":"P Nuhn","year":"2009","unstructured":"Nuhn P, K\u00fcnzli BM, Hennig R, Mitkus T, Ramanauskas T, Nobiling R, et al. Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo. Mol Cancer. 2009;8:37.","journal-title":"Mol Cancer"},{"issue":"3","key":"2671_CR32","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313\u201323.","journal-title":"Cell Stem Cell"},{"key":"2671_CR33","doi-asserted-by":"crossref","unstructured":"Low RRJ, Lim WW, Nguyen PM, Lee B, Christie M, Burgess AW, et al. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids. Cancers (Basel). 2021;13(19):4979.","DOI":"10.3390\/cancers13194979"},{"issue":"1","key":"2671_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1541-7786.MCR-18-0531","volume":"17","author":"I Romero-Calvo","year":"2019","unstructured":"Romero-Calvo I, Weber CR, Ray M, Brown M, Kirby K, Nandi RK, et al. Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors. Molecular Cancer Res. 2019;17(1):70\u201383.","journal-title":"Molecular Cancer Res"},{"key":"2671_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fonc.2020.00553","volume":"10","author":"JT Sharick","year":"2020","unstructured":"Sharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL, Esbona K, et al. Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Front Oncol. 2020;10:553.","journal-title":"Front Oncol"},{"issue":"1","key":"2671_CR36","doi-asserted-by":"publisher","first-page":"e1006596","DOI":"10.1371\/journal.pcbi.1006596","volume":"15","author":"DMA Gendoo","year":"2019","unstructured":"Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, et al. Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. PLoS Comput Biol. 2019;15(1):e1006596.","journal-title":"PLoS Comput Biol"},{"key":"2671_CR37","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3389\/fonc.2019.00875","volume":"9","author":"SI Choi","year":"2019","unstructured":"Choi SI, Jeon AR, Kim MK, Lee YS, Im JE, Koh JW, et al. Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. Front Oncol. 2019;9:875.","journal-title":"Front Oncol"},{"issue":"1","key":"2671_CR38","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1038\/s41467-022-29684-9","volume":"13","author":"JK Nelson","year":"2022","unstructured":"Nelson JK, Thin MZ, Evan T, Howell S, Wu M, Almeida B, et al. USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer. Nat Commun. 2022;13(1):2070.","journal-title":"Nat Commun"},{"issue":"11","key":"2671_CR39","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","volume":"103","author":"Y Nakai","year":"2010","unstructured":"Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer. 2010;103(11):1644\u20138.","journal-title":"Br J Cancer"},{"issue":"2","key":"2671_CR40","first-page":"355","volume":"22","author":"R Noguchi","year":"2009","unstructured":"Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep. 2009;22(2):355\u201360.","journal-title":"Oncol Rep"},{"issue":"1","key":"2671_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2009.06.011","volume":"16","author":"DD Von Hoff","year":"2009","unstructured":"Von Hoff DD, Korn R, Mousses S. Pancreatic cancer\u2013could it be that simple? A different context of vulnerability. Cancer Cell. 2009;16(1):7\u20138.","journal-title":"Cancer Cell"},{"issue":"34","key":"2671_CR42","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29(34):4548\u201354.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2671_CR43","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/cas.13694","volume":"109","author":"R Feng","year":"2018","unstructured":"Feng R, Morine Y, Ikemoto T, Imura S, Iwahashi S, Saito Y, et al. Nab-paclitaxel interrupts cancer-stromal interaction through C-X-C motif chemokine 10-mediated interleukin-6 downregulation in vitro. Cancer Sci. 2018;109(8):2509\u201319.","journal-title":"Cancer Sci"},{"issue":"4","key":"2671_CR44","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/bjc.2013.415","volume":"109","author":"R Alvarez","year":"2013","unstructured":"Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109(4):926\u201333.","journal-title":"Br J Cancer"},{"key":"2671_CR45","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/ncomms3516","volume":"4","author":"VP Chauhan","year":"2013","unstructured":"Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013;4:2516.","journal-title":"Nat Commun"},{"issue":"1","key":"2671_CR46","doi-asserted-by":"publisher","first-page":"19943","DOI":"10.1038\/s41598-021-99412-8","volume":"11","author":"K Hachiya","year":"2021","unstructured":"Hachiya K, Masuya M, Kuroda N, Yoneda M, Tsuboi J, Nagaharu K, et al. Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1\/CCR2 pathway. Sci Rep. 2021;11(1):19943.","journal-title":"Sci Rep"},{"key":"2671_CR47","doi-asserted-by":"crossref","unstructured":"Morsy MA, Abdelraheem WM, El-Hussieny M, and Refaie MMM. Protective Effects of Irbesartan, an Angiotensin Receptor Blocker with PPARgamma Agonistic Activity, against Estradiol Benzoate-Induced Endometrial Hyperplasia and Atypia in Female Rats via Modulation of TNFalpha\/Survivin Pathway. Pharmaceuticals (Basel). 2021;14(7):649.","DOI":"10.3390\/ph14070649"},{"issue":"4","key":"2671_CR48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","volume":"150","author":"FX Yu","year":"2012","unstructured":"Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150(4):780\u201391.","journal-title":"Cell"},{"key":"2671_CR49","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canlet.2018.07.021","volume":"434","author":"S Saikawa","year":"2018","unstructured":"Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, et al. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein. Cancer Lett. 2018;434:120\u20139.","journal-title":"Cancer Lett"},{"issue":"10","key":"2671_CR50","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/ng.3398","volume":"47","author":"RA Moffitt","year":"2015","unstructured":"Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168\u201378.","journal-title":"Nat Genet"},{"issue":"4","key":"2671_CR51","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm.2344","volume":"17","author":"EA Collisson","year":"2011","unstructured":"Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500\u20133.","journal-title":"Nat Med"},{"issue":"12","key":"2671_CR52","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.trecan.2022.08.005","volume":"8","author":"E Espinet","year":"2022","unstructured":"Espinet E, Klein L, Pure E, Singh SK. Mechanisms of PDAC subtype heterogeneity and therapy response. Trends Cancer. 2022;8(12):1060\u201371.","journal-title":"Trends Cancer"},{"issue":"6","key":"2671_CR53","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","volume":"155","author":"F Puleo","year":"2018","unstructured":"Puleo F, Nicolle R, Blum Y, Cros J, Marisa L, Demetter P, et al. Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. Gastroenterology. 2018;155(6):1999-2013 e3.","journal-title":"Gastroenterology."},{"issue":"2","key":"2671_CR54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O\u2019Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52(2):231\u201340.","journal-title":"Nat Genet"},{"issue":"11","key":"2671_CR55","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s43018-021-00258-w","volume":"2","author":"M Tu","year":"2021","unstructured":"Tu M, Klein L, Espinet E, Georgomanolis T, Wegwitz F, Li X, et al. TNF-alpha-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat Cancer. 2021;2(11):1185\u2013203.","journal-title":"Nat Cancer"},{"key":"2671_CR56","doi-asserted-by":"crossref","unstructured":"Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, et al. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight. 2019;4(21):e130811.","DOI":"10.1172\/jci.insight.130811"},{"issue":"4","key":"2671_CR57","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663\u201376.","journal-title":"Cell"},{"issue":"1","key":"2671_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.stem.2007.05.014","volume":"1","author":"N Maherali","year":"2007","unstructured":"Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007;1(1):55\u201370.","journal-title":"Cell Stem Cell"},{"issue":"7151","key":"2671_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313\u20137.","journal-title":"Nature"},{"issue":"13","key":"2671_CR60","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1158\/0008-5472.CAN-12-4085","volume":"73","author":"CC Chang","year":"2013","unstructured":"Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, et al. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 2013;73(13):4147\u201357.","journal-title":"Cancer Res"},{"issue":"2","key":"2671_CR61","first-page":"2176","volume":"13","author":"J Lang","year":"2019","unstructured":"Lang J, Zhao X, Wang X, Zhao Y, Li Y, Zhao R, et al. Targeted Co-delivery of the Iron Chelator Deferoxamine and a HIF1alpha Inhibitor Impairs Pancreatic Tumor Growth. ACS Nano. 2019;13(2):2176\u201389.","journal-title":"ACS Nano"},{"issue":"6486","key":"2671_CR62","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aaw9872","volume":"368","author":"MA Badgley","year":"2020","unstructured":"Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science (New York, NY). 2020;368(6486):85\u20139.","journal-title":"Science (New York, NY)"},{"issue":"1","key":"2671_CR63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF02829934","volume":"1","author":"G Cairo","year":"2006","unstructured":"Cairo G, Bernuzzi F, Recalcati S. A precious metal: Iron, an essential nutrient for all cells. Genes Nutr. 2006;1(1):25\u201339.","journal-title":"Genes Nutr"},{"issue":"52","key":"2671_CR64","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1038\/sj.onc.1205925","volume":"21","author":"G Marziali","year":"2002","unstructured":"Marziali G, Perrotti E, Ilari R, Lulli V, Coccia EM, Moret R, et al. Role of Ets-1 in transcriptional regulation of transferrin receptor and erythroid differentiation. Oncogene. 2002;21(52):7933\u201344.","journal-title":"Oncogene"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02671-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02671-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02671-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:04:23Z","timestamp":1683158663000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02671-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02671-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"20 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The usage of these specimens and the patients\u2019 information were approved by the Ethics Committee of the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) and the Ethics Committee of the Tongliao City Hospital (Tongliao, China). All patients provided written consent for the use of their specimens and disease information for future investigations according to the ethics committee and in accordance with recognized ethical guidelines of Helsinki (ID number of the ethics approval: AE-2021121 and 2021024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The content of this paper has not been submitted to any other scientific publications. All the authors have declared that no financial conflict of interest exists. All authors of this interdisciplinary team have approved the submission of this work for publication in Journal of Experimental & Clinical Cancer Research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no conflict of interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}],"article-number":"111"}}